Slingshot Biosciences Announces $23 Million In Series A Financing

Slingshot Biosciences, a biotechnology company building the world’s first on-demand synthetic cell platform, today announced the closing of $23 million in a Series A financing. The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital. The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies. Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors